Severe Inflammatory Idiopathic Multicentric Castleman's Disease Coexisting with Advanced Renal Cancer: A Case Report.


Journal

The Tohoku journal of experimental medicine
ISSN: 1349-3329
Titre abrégé: Tohoku J Exp Med
Pays: Japan
ID NLM: 0417355

Informations de publication

Date de publication:
08 Jun 2022
Historique:
pubmed: 15 4 2022
medline: 11 6 2022
entrez: 14 4 2022
Statut: ppublish

Résumé

The present case study was conducted on a 74-year-old man who visited our department due to a left renal and retroperitoneal tumor on computed tomography (CT). The patient was diagnosed with left renal cancer lymph node metastasis and was hospitalized a few weeks prior to surgery due to fever, malaise, and severe appetite loss. Biochemical laboratory findings at admission showed markedly high levels of inflammation. The cause of high inflammatory response was paraneoplastic syndrome. Tumor resection was considered necessary, and left nephrectomy and lymphadenectomy were performed; however, it did not improve the inflammatory response. After operation, positron emission tomography-CT revealed hyperaccumulation of 18F-fluorodeoxyglucose in the bone marrow throughout the body. Pathological examination of the resected specimen and bone marrow aspiration revealed the coexistence of idiopathic multicentric Castleman disease (CD) and renal cancer. Prednisolone and tocilizumab were administered for idiopathic multicentric CD and a tyrosine kinase inhibitor for renal cancer; however, they had poor therapeutic effect, and the patient died. CD is characterized by systemic symptoms due to the overproduction of interleukin-6. Treatment for idiopathic multicentric CD involves steroid and anti-interleukin-6 therapy. The diagnostic criteria for CD require the exclusion of malignant tumors although there are some cases in which CD and malignant tumors coexist. The prognosis for CD is relatively good; however, as in this case, the prognosis of CD coexisting with uncontrollable renal cancer is insufficient due to poor improvement in the inflammatory response.

Identifiants

pubmed: 35418533
doi: 10.1620/tjem.2022.J025
doi:

Substances chimiques

Fluorodeoxyglucose F18 0Z5B2CJX4D

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

127-133

Auteurs

Daigo Chiba (D)

Department of Urology, Tohoku University Graduate School of Medicine.

Yoshihide Kawasaki (Y)

Department of Urology, Tohoku University Graduate School of Medicine.

Atsushi Miyagi (A)

Department of Urology, Tohoku University Graduate School of Medicine.

Yuki Katsumata (Y)

Department of Urology, Tohoku University Graduate School of Medicine.

Yohei Satake (Y)

Department of Urology, Tohoku University Graduate School of Medicine.

Shuichi Shimada (S)

Department of Urology, Tohoku University Graduate School of Medicine.

Hiromichi Katayama (H)

Department of Urology, Tohoku University Graduate School of Medicine.

Naoki Kawamorita (N)

Department of Urology, Tohoku University Graduate School of Medicine.

Shinichi Yamashita (S)

Department of Urology, Tohoku University Graduate School of Medicine.

Koji Mitsuzuka (K)

Department of Urology, Tohoku University Graduate School of Medicine.

Kanae Akita (K)

Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine.

Mika Watanabe (M)

Department of Pathology, Tohoku University Hospital.

Akihiro Ito (A)

Department of Urology, Tohoku University Graduate School of Medicine.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH